Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1

Abstract

Thioredoxin (Trx) is a cellular redox enzyme that plays multiple roles in regulating cell growth and apoptosis. Jun activation domain-binding protein 1 (Jab1) was originally identified as a coactivator of activator protein 1 (AP-1) transcription and was also shown to promote degradation of the cyclin-dependent kinase inhibitor, p27Kip1. Recently, Jab1 expression was associated with the progression and poor prognosis of pituitary, epithelial ovarian, and breast cancers, suggesting that it plays a role in oncogenesis. Here, we report that Trx specifically interacts with and modulates the function of Jab1. Fluorescence resonance energy transfer and co-immunoprecipitation studies revealed that Trx and Jab1 colocalize and directly interact with each other. Further, Trx negatively regulates two important Jab1-controlled signaling pathways, activation of AP-1 transcription and degradation of p27Kip1, probably through a direct interaction between Trx and C-terminal of Jab1. The negative effect of Trx on AP-1 activity is Jab1-dependent, as it disappears when Jab1 levels are suppressed by an antisense approach. In addition, Trx competes with p27Kip1 for Jab1 binding. Taken together, our results suggest that Trx may regulate cell cycle and growth through a novel modulation of Jab1-mediated proliferation signals, further indicating that Trx may have the ability to control tumor progression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR and Kim KW . (2002). J. Biol. Chem., 277, 9–12.

  • Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C and Dubiel W . (2001). EMBO J., 20, 1630–1639.

  • Caballero OL, Resto V, Patturajan M, Meerzaman D, Guo MZ, Engles J, Yochem R, Ratovitski E, Sidransky D and Jen J . (2002). Oncogene, 21, 3003–3010.

  • Chamovitz DA and Segal D . (2001). EMBO Rep, 2, 96–101.

  • Chen X, Li Y, Wei K, Li L, Liu W, Zhu Y, Qiu Z and He F . (2003). J. Biol. Chem., 278, 49022–49030.

  • Claret FX, Hibi M, Dhut S, Toda T and Karin M . (1996). Nature, 383, 453–457.

  • Deng XW, Dubiel W, Wei N, Hofmann K, Mundt K, Colicelli J, Kato J, Naumann M, Segal D, Seeger M, Carr A, Glickman M and Chamovitz DA . (2000). Trends Genet., 16, 202–203.

  • Finkel T . (2003). Curr. Opin. Cell Biol., 15, 247–254.

  • Hayashi T, Ueno Y and Okamoto T . (1993). J. Biol. Chem., 268, 11380–11388.

  • Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K and Yodoi J . (1997). Proc. Natl. Acad. Sci. USA, 94, 3633–3638.

  • Holmgren A . (1985). Annu. Rev. Biochem., 54, 237–271.

  • Holmgren A . (1989). J. Biol. Chem., 264, 13963–13966.

  • Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H, Kakudo K, Kuma K and Miyauchi A . (2003). Anticancer Res., 23, 4121–4125.

  • Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG and Choi I . (2000). J. Immunol., 164, 6287–6295.

  • Karpova TS, Baumann CT, He L, Wu X, Grammer A, Lipsky P, Hager GL and McNally JG . (2003). J. Microsc., 209, 56–70.

  • Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H and Bernhagen J . (2000). Nature, 408, 211–216.

  • Kleemann R, Kapurniotu A, Mischke R, Held J and Bernhagen J . (1999). Eur. J. Biochem., 261, 753–766.

  • Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX and Grossman AB . (2002). J. Clin. Endocrinol. Metab., 87, 2635–2643.

  • Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C and Claret FX . (2003). Cancer Res., 63, 2977–2981.

  • Lee SR, Kwon KS, Kim SR and Rhee SG . (1998). J. Biol. Chem., 273, 15366–15372.

  • Li S, Liu X and Ascoli M . (2000). J. Biol. Chem., 275, 13386–13393.

  • Lu C, Li Y, Zhao Y, Xing G, Tang F, Wang Q, Sun Y, Wei H, Yang X, Wu C, Chen J, Guan KL, Zhang C, Chen H and He F . (2002). FASEB J., 16, 90–92.

  • Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I and Tanaka H . (1999). J. Biol. Chem., 274, 3182–3188.

  • Matthews JR, Wakasugi N, Virelizier JL, Yodoi J and Hay RT . (1992). Nucleic Acids Res., 20, 3821–3830.

  • Patterson GH, Piston DW and Barisas BG . (2000). Anal. Biochem., 284, 438–440.

  • Powis G, Mustacich D and Coon A . (2000). Free Radic. Biol. Med., 29, 312–322.

  • Qin J, Clore GM, Kennedy WM, Huth JR and Gronenborn AM . (1995). Structure, 3, 289–297.

  • Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ and Medeiros LJ . (2003). Clin. Cancer Res., 9, 1121–1128.

  • Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K and Ichijo H . (1998). EMBO J., 17, 2596–2606.

  • Schenk H, Klein M, Erdbrugger W, Droge W and Schulze-Osthoff K . (1994). Proc. Natl. Acad. Sci. USA, 91, 1672–1676.

  • Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R, Gordon C, Naumann M and Dubiel W . (1998). FASEB J., 12, 469–478.

  • Senkevich TG, White CL, Koonin EV and Moss B . (2000). Proc. Natl. Acad. Sci. USA, 97, 12068–12073.

  • Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y and Tokuda M . (2001). Clin. Cancer Res., 7, 4130–4135.

  • Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, Yoshida M, Yoneda-Kato N and Kato JY . (2002). J. Biol. Chem., 277, 2302–2310.

  • Tomoda K, Kubota Y and Kato J . (1999). Nature, 398, 160–165.

  • Truong K and Ikura M . (2001). Curr. Opin. Struct. Biol., 11, 573–578.

  • Wei N, Tsuge T, Serino G, Dohmae N, Takio K, Matsui M and Deng XW . (1998). Curr. Biol., 8, 919–922.

  • Xanthoudakis S and Curran T . (1992). EMBO J., 11, 653–665.

  • Xanthoudakis S, Miao GG and Curran T . (1994). Proc. Natl. Acad. Sci. USA, 91, 23–27.

  • Yodoi J, Masutani H and Nakamura H . (2001). Biofactors, 15, 107–111.

Download references

Acknowledgements

We thank Drs J Yodoi and I Choi for providing the Trx mammalian expression vectors. We also thank Drs PG Suh and KK Park for helpful discussion and providing reagents, Dr JS Lim for FACS analysis, HA Hwang and EH Ryu for technical support, and Korea Basic Science Institute for confocal microscopy. This work was supported by Grants M1-0016000042 and M1030914 from the Korea Ministry of Science and Technology, and Grant R01-1999-00068 from the Korea Science and Engineering Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ki-Sun Kwon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hwang, C., Ryu, Y., Chung, MS. et al. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene 23, 8868–8875 (2004). https://doi.org/10.1038/sj.onc.1208116

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208116

Keywords

This article is cited by

Search

Quick links